Quick Answer
Oruka Therapeutics, Inc. reported Cash and Equivalents of $46.94 million for fiscal year 2025.
Oruka Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $46.94M | -23.8% |
| 2024 | $61.58M | +64.5% |
| 2023 | $37.43M | -11.8% |
| 2022 | $42.45M | -20.5% |
| 2021 | $53.36M | +8.7% |
| 2020 | $49.07M | +486.8% |
| 2019 | $8.36M | +26.6% |
| 2018 | $6.61M | -24.1% |
| 2017 | $8.70M | +17.6% |
| 2016 | $7.40M | -80.9% |
| 2015 | $38.80M | +152.7% |
| 2014 | $15.35M | -8.4% |
| 2013 | $16.76M | +473.8% |
| 2012 | $2.92M | -50.9% |
| 2011 | $5.94M | -15.4% |
| 2010 | $7.03M | -9.5% |
| 2009 | $7.76M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $91.25M | -77.8% | +39.5% |
| June 30, 2025 | $65.40M | +96.5% | -21.7% |
| March 31, 2025 | $83.57M | +132.8% | +35.7% |
| December 31, 2024 | $61.58M | +64.5% | -85.0% |
| September 30, 2024 | $410.88M | +967.6% | +1134.5% |
| June 30, 2024 | $33.28M | -17.1% | -7.3% |
| March 31, 2024 | $35.90M | -12.1% | -4.1% |
| December 31, 2023 | $37.43M | -11.8% | -2.7% |
- Oruka Therapeutics, Inc. showed a decrease of -23.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2025 period, Oruka Therapeutics, Inc.’s cash and equivalents has grown by 504.6% (from $7.76 million to $46.94 million).
- The most recent figure is from Oruka Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: